{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:metostilenol [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Metostilenol was developed as an antidepressant. However, it has never been marketed.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Xenbucin is an antihyperlipidemic agent. Information about the current use of this agent is not available.
Status:
Investigational
Source:
INN:xenthiorate [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Xenthiorate was studied as an antihyperlipidemic agent. Information about the current use of this agent is not available.
Class (Stereo):
CHEMICAL (UNKNOWN)
Octamoxine (ximaol), a monoamine oxidase inhibitor was used as an antidepressant to treat mental depression. Now this drug is no longer marketed.
Class (Stereo):
CHEMICAL (UNKNOWN)
Octamoxine (ximaol), a monoamine oxidase inhibitor was used as an antidepressant to treat mental depression. Now this drug is no longer marketed.
Class (Stereo):
CHEMICAL (RACEMIC)
Manozodil is a vasodilator agent.
Status:
Investigational
Source:
NCT01415297: Phase 1 Interventional Completed Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01803074: Phase 2 Interventional Completed Infection, Human Immunodeficiency Virus
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (RACEMIC)
Butaverine is a fatty acid ester with antispasmodic activity which was under development for treatment urinary incontinence
Status:
Investigational
Source:
NCT04032080: Phase 2 Interventional Completed Triple Negative Breast Cancer
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
LY2606368 (Prexasertib) is a small-molecule Chk-1 inhibitors invented by Array and being developed by Eli Lilly and Company. Lilly is responsible for all clinical development and commercialization activities. LY2606368 is advancing in Phase 2 clinical trials for cancer. Prexasertib preferentially binds to and inhibits CHK1 and, to a lesser extent, inhibits CHK2. Chk-1 is a protein kinase that regulates the tumor cell's response to DNA damage often caused by treatment with chemotherapy. In response to DNA damage, Chk-1 blocks cell cycle progression in order to allow for repair of damaged DNA, thereby limiting the efficacy of chemotherapeutic agents. Inhibiting Chk-1 in combination with chemotherapy can enhance tumor cell death by preventing these cells from recovering from DNA damage.
